The only penny stocks site recommended in Barron's and by Forbes.

Online since 1996, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX.

To learn what this site is really about, we urge you to visit the Overview and Track Record pages. However, before doing so, take a glance at a few of our all-time penny stocks winners. Of course, these are the subsequent gains reached once they hit our target prices and we closed the positions, but it is fun to ponder. The first price was the initial recommendation, followed by the subsequent high, and the eventual ultimate percentage gain. No doubt, you will recognize most of these companies.

Netegrity
(acquired by IBM)
 $2.18 to $73.20 3487%
Inhibitex
(acquired by BristolMyersSquibb)
 $2.35 to $24.08 925%
Cellstar $1.44 to $13.50 837%
Iomega $3.25 to $13.90 328%
Nanophase $3.75 to $16.75 347%
Immunomedics $1.44 to $29.12 1922%
Total Renal Care $3.12 to $26.95 741%
Voxware $ .90 to $10.31 1046%
Corvas $3.00 to $23.25 675%
Cytogen $2.12 to $17.50 725%
Verilink $3.00 to $14.62 387%
GeneLabs $2.31 to $10.72 364%

26 ANALYSTS SAY BUY THIS $2.70 PENNY STOCK!

We are about to recommend in our very next Newsletter our first-ever penny stocks pick that is a STRONG BUY/BUY of over two dozen analysts.  Never before in our twenty years of Internet publishing have we ever seen anything quite like this.  Of course, our current subscribers will know about this on the day it happens, so, if you want to be one of them, SUBSCRIBE NOW!

BTW, the late April penny stocks Newsletter is now live.  Featured are a robotics maker and a diagnostics developer (see the box to your right).

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

 
New! Join our Penny Stocks Forum
(Note: this is separate from the Newsletter)
RIGHT NOW!
IN THE LATE APRIL 2018 NEWSLETTER

IMPORTANT! We now have nearly 20 second-time penny stocks picks in our Current Portfolio, so there are a lot to pick from. Read about "OUR NEW PROVEN CHANNELING STRATEGY!"

FOUR ANALYSTS rate this diagnostics maker a STRONG BUY/BUY that is developing molecular cancer diagnostics that identify genetic markers of various cancers; trading near its 52-week low at around $2.20.

THREE ANALYSTS rate this robotics maker a STRONG BUY/BUY that sells devices for the wheelchair-bound and is making a lot of inroads to get their products covered through medical insurance in multiple countries; trading near its 52-week low at around $1.05. THIS IS REAL IMPORANT!!!!!!!! Here is another Channeled stock pick that worked great the first time around. READ ABOUT OUR PROVEN CHANNELING STRATEGY!

Our New
Proven Strategy

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

Forbes Directory - Best of the Web
Best of the Web
(Small Caps)
Barron's > read
review
As Featured:
*BARRON's
*CNNfn.com
*BusinessWeek Online
*Barron's Electronic Edition
InvestOnlineTrading
Ads From Google

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

The only penny stocks site recommended in Barron's and by Forbes, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX. Penny stock trading involves substantial risk, so always research every recommendation before trading, consult with licensed professionals before trading, and always trade with caution. The recommendations listed in the Newsletter are only for investment ideas and are not solicitations to purchase equities. For more extensive details, view the Privacy Policy and Disclaimer page.
Ads From Google